LAGEVRIO
Total Payments
$6.1M
Transactions
767
Doctors
190
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.1M | 557 | 189 |
| 2023 | $4.0M | 210 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.1M | 368 | 99.5% |
| Travel and Lodging | $19,095 | 83 | 0.3% |
| Food and Beverage | $10,777 | 315 | 0.2% |
| Consulting Fee | $2,441 | 1 | 0.0% |
Payments by Type
Research
$6.1M
368 transactions
General
$32,313
399 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Evaluate the Pharmacokinetics and Definitive Bioequivalence ofMolnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants | Merck Sharp & Dohme LLC | $1.9M | 0 |
| A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression | Merck Sharp & Dohme LLC | $1.7M | 0 |
| A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression | Merck Sharp & Dohme LLC | $804,331 | 0 |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 Laboratory-confirmed SARS-CoV-2 Infection With Symptoms in Adults Residing With a Person With COVID-19 | Merck Sharp & Dohme LLC | $658,478 | 0 |
| An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Molnupiravir MK-4482 MOV in Participants with Severe Renal Impairment. | Merck Sharp & Dohme LLC | $459,620 | 0 |
| An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of Molnupiravir MK-4482 in Participants with Moderate Hepatic Impairment | Merck Sharp & Dohme LLC | $353,898 | 0 |
| A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. | Merck Sharp & Dohme LLC | $119,403 | 0 |
| A Phase 2,3 Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19 | Merck Sharp & Dohme LLC | $83,483 | 0 |
Top Doctors Receiving Payments for LAGEVRIO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boerne, TX | $6.1M | 381 |
| , MD | Gynecology | Washington, DC | $2,441 | 1 |
| , M.D | Internal Medicine | Los Alamitos, CA | $2,374 | 14 |
| Bob Hutchins | Emergency Medicine | Jackson, MS | $2,295 | 12 |
| , AGCNS-BC | Clinical Nurse Specialist | Grosse Pointe Woods, MI | $1,776 | 14 |
| , MD | Infectious Disease | Grosse Pointe Woods, MI | $1,739 | 14 |
| Kevin Oei | Family Medicine | Downey, CA | $1,725 | 13 |
| , M.D | Family Medicine | Atlanta, GA | $1,557 | 12 |
| , ANP-C | Nurse Practitioner | Teaneck, NJ | $1,515 | 13 |
| , M.D | General Practice | San Juan, PR | $1,506 | 13 |
| , RN, FNP-C | Family | Houston, TX | $1,457 | 12 |
| , M.D | Family Medicine | Fayette, MS | $1,383 | 10 |
| , M.D | General Practice | Miami, FL | $1,342 | 12 |
| , MD | Internal Medicine | San Juan, PR | $1,272 | 9 |
| , A.P.N | Gerontology | Jackson, TN | $1,125 | 6 |
| , MD | Pediatrics | Miami, FL | $1,056 | 8 |
| , APRN | Family | Port Saint Lucie, FL | $729.78 | 10 |
| , M.D | Internal Medicine | Miami, FL | $658.88 | 6 |
| , M.D | Family Medicine | Miami, FL | $653.66 | 5 |
| , MD | Anatomic Pathology & Clinical Pathology | San Diego, CA | $69.75 | 2 |
| , APRN | Family | Miami Lakes, FL | $68.52 | 2 |
| , NP | Family | New York, NY | $67.02 | 2 |
| , D.O | Family Medicine | New York, NY | $67.02 | 2 |
| , MD | Internal Medicine | New York, NY | $64.90 | 2 |
| , M.D | Family Medicine | New York, NY | $64.90 | 2 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme LLC $6.1M
Product Information
- Type Drug
- Total Payments $6.1M
- Total Doctors 190
- Transactions 767
About LAGEVRIO
LAGEVRIO is a drug associated with $6.1M in payments to 190 healthcare providers, recorded across 767 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme LLC.
Payment data is available from 2023 to 2024. In 2024, $2.1M was paid across 557 transactions to 189 doctors.
The most common payment nature for LAGEVRIO is "Unspecified" ($6.1M, 99.5% of total).
LAGEVRIO is associated with 8 research studies, including "A Study to Evaluate the Pharmacokinetics and Definitive Bioequivalence ofMolnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants" ($1.9M).